We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Non-Cystic Fibrosis Bronchiectasis Study

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas aeruginosa Infection

lung illustration
Age: 18+ years old
Sex at Birth: All
Healthy Participants: No
Type: Interventional Treatment
Condition: Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa
Compensation: Yes
Location: University Hospitals Medical Centers

Learn More About This Research Study

For more information, please contact study coordinator Briana Jackson at 216-983-0891 or by completing the form below.

Study Purpose

The main purpose of this research study is to learn how well the investigational study drug works; how long the study drug stays and works in the airway, and how safe the study drug is when taken alone (or in combination with inhaled antibiotics) compared with placebo and inhaled antibiotics alone. A placebo is an inactive material that looks like the study drug but does not have any active study drug. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.

Who Can Participate

Participants 18 years of age or older with non-cystic fibrosis bronchiectasis or chronic pulmonary pseudomonoas aeruginosa may be eligible of this research study.

Request More Information

Please complete the form below to be contacted by a study representative and learn more about this study.

I'm not a robot

  • STUDY20231258